Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.


Cancer Immunotherapy: Advances in Combination Therapies

Cancer Immunotherapy: Advances in Combination Therapies
Reported by
Jordana Thibado

Posted July 22, 2020

Jordana Thibado is a New York City-based biophysics PhD candidate and science writer.

Presented By

Cancer Discussion Group

The New York Academy of Sciences

Immunotherapy, which harnesses the immune system to target and attack cancer cells, has emerged as a revolutionary approach to cancer treatment. Despite its effectiveness for a wide range of cancers, eligibility for treatment is dependent on the patient’s immune system, age, and genetic profile, as well as how advanced the cancer is and whether it has responded to prior treatment. Current research aims to improve treatment strategies and better predict patient outcomes. On May 11-12, 2020, the New York Academy of Sciences hosted the annual Frontiers in Cancer Immunotherapy symposium. Experts in tumor immunology, cancer genetics, and computational biology discussed novel therapeutic targets, tumor evolution, and the mechanisms driving resistance to current treatment. Learn about the latest research advances in cancer immunotherapy in this summary.


Symposium Highlights

  • Computational neoantigen model predicts cancer patient outcomes. >
  • Combination immunotherapy produces new T cells that extend patient survival. >
  • Personalized cancer vaccines demonstrate therapeutic benefits. >
  • New computational genomics tools provide pediatric cancer insight. >
  • Immune checkpoint inhibitor associated toxicity yields new clinical syndrome. >
  • Macrophage reprogramming can halt metastatic cancer progression. >
  • Immune cell “neighborhoods” are altered during cancer progression. >
  • Multi-specific CAR T cell therapy may reduce immunotherapy resistance. >
Advances Immune Checkpoint Therapies
Beyond Immune Checkpoint Inhibitors
Toxicity, Tumor Response, and Microenvironment
Immunopathology and Engineered Immune Cells